Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
11.68
+0.38 (3.36%)
Dec 20, 2024, 4:00 PM EST - Market closed
Stoke Therapeutics Revenue
Stoke Therapeutics had revenue of $4.89M in the quarter ending September 30, 2024, with 47.94% growth. This brings the company's revenue in the last twelve months to $16.74M, up 81.08% year-over-year. In the year 2023, Stoke Therapeutics had annual revenue of $8.78M, down -29.22%.
Revenue (ttm)
$16.74M
Revenue Growth
+81.08%
P/S Ratio
35.57
Revenue / Employee
$152,209
Employees
110
Market Cap
618.65M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cross Country Healthcare | 1.45B |
Varex Imaging | 811.00M |
Pharming Group | 285.75M |
Fulgent Genetics | 277.76M |
GRAIL | 117.67M |
Capricor Therapeutics | 23.23M |
Altimmune | 52.00K |
STOK News
- 15 days ago - Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome - Business Wire
- 16 days ago - GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners - Business Wire
- 17 days ago - Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome - Business Wire
- 19 days ago - Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting - Business Wire
- 6 weeks ago - Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates - Business Wire
- 3 months ago - Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome - Business Wire
- 3 months ago - Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome - Seeking Alpha
- 3 months ago - Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer - Business Wire